1,273 results match your criteria Journal of Clinical Lipidology [Journal]


Clinical features, molecular characteristics, and treatments of a Chinese girl with sitosterolemia: A case report and literature review.

J Clin Lipidol 2019 Jan 22. Epub 2019 Jan 22.

Department of Genetics and Endocrinology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China. Electronic address:

Sitosterolemia is a rare autosomal recessive disease characterized by a significant increase in blood plant sterol levels. Clinical manifestations usually include xanthomas, hypercholesterolemia,premature atherosclerosis and hematological abnormalities. We report here a sitosterolemia patient who presented with multiple xanthomas and profound hypercholesterolemia since 3 years old. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.007DOI Listing
January 2019

Relationship of NEFA concentrations to RBP4 and to RBP4/retinol in prepubertal children with and without obesity.

J Clin Lipidol 2019 Jan 23. Epub 2019 Jan 23.

Lipid Metabolism Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, Spain.

Background: The regulation of adipose tissue metabolism in early childhood obesity is not well understood. Insulin levels are higher and insulin resistance seems to be present in prepubertal children with obesity but, differing from their behavior in adults with obesity, non-esterified fatty acid (NEFA) concentrations are not increased. Retinol-binding protein (RBP)-4 concentration is associated with obesity and insulin resistance conditions, but the means of this relationship remain unclear, and few studies have taken retinol values into account to evaluate it. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.006DOI Listing
January 2019
1 Read

JCL roundtable: Coronary artery calcium scoring and other vascular imaging for risk assessment.

J Clin Lipidol 2019 Jan - Feb;13(1):4-14

Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

Computed tomographic (CT) coronary calcium scoring has been established by large prospective, population-based studies as the single best noninvasive predictor of atherosclerotic cardiovascular risk available today. The calcium score correlates highly with the total burden of coronary atherosclerosis demonstrated at autopsy. It adds significantly to traditional risk calculators such as the Framingham Risk Calculator or the Pooled Cohort Equations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.008DOI Listing
February 2019
1 Read

From the editor: Humans are animals and therefore make saturated fat.

Authors:
John R Guyton

J Clin Lipidol 2019 Jan - Feb;13(1):1-2

Professor of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.001DOI Listing
February 2019

Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency.

J Clin Lipidol 2019 Jan 11. Epub 2019 Jan 11.

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Community Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Cardiology, Rinku General Medical Center, Osaka, Japan. Electronic address:

Background: We previously reported that the patients with cholesteryl ester transfer protein (CETP) deficiency (CETP-D) show marked changes in the size and lipid compositions of high-density lipoprotein (HDL) and that they are not protected from atherosclerotic cardiovascular diseases, despite increased serum HDL-cholesterol (HDL-C) levels. HDL particles carry a variety of proteins, some of which are known to have antiatherogenic functions.

Objective: This study aimed to investigate the protein composition of HDL particles in patients with CETP-D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.002DOI Listing
January 2019

Detection of the benign c.2579C>T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia.

J Clin Lipidol 2019 Jan 16. Epub 2019 Jan 16.

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan. Electronic address:

Background: More than 2500 variants of the low-density lipoprotein receptor (LDLR) gene have been reported in familial hypercholesterolemia (FH). However, the effects of these variants on the pathophysiology of FH have not been fully clarified.

Objective: Our aim was to examine whether the c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.004DOI Listing
January 2019

Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.

J Clin Lipidol 2019 Jan 14. Epub 2019 Jan 14.

Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

Background: Access to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors that lower low-density lipoprotein cholesterol in patients at high risk of atherosclerotic cardiovascular disease events has proven challenging. Methods to overcome access barriers are needed to fully realize the benefits of these novel agents.

Objective: This study evaluated medication access rates in patients prescribed a PCSK9 inhibitor at a health care system with integrated specialty pharmacy services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.003DOI Listing
January 2019

A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice.

J Clin Lipidol 2019 Jan 16. Epub 2019 Jan 16.

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%.

Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2019.01.005DOI Listing
January 2019

A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy.

J Clin Lipidol 2018 Dec 19. Epub 2018 Dec 19.

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. Electronic address:

Lipoprotein glomerulopathy (LPG) is a rare autosomal dominant renal disease with incomplete penetrance, associated with specific protein-modifying mutations in the APOE gene. LPG is associated with poor renal prognosis, in which lipoprotein thrombi are seen in the glomerular capillaries. Dyslipidemia in LPG generally resembles type III hyperlipoproteinemia with elevated serum apolipoprotein E level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.12.004DOI Listing
December 2018
4 Reads

Small HDL subclass is associated with coronary plaque stability: An optical coherence tomography study in patients with coronary artery disease.

J Clin Lipidol 2018 Dec 15. Epub 2018 Dec 15.

Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China. Electronic address:

Background: The role of high-density lipoprotein (HDL) subclasses in atherosclerotic diseases remains an open question. Previous clinical trials have attempted to explore the predictive effect of HDL subspecies on cardiovascular risk. However, no studies have assessed the connections between these subclasses and characteristics of plaque microstructure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.12.002DOI Listing
December 2018

Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women.

J Clin Lipidol 2018 Dec 18. Epub 2018 Dec 18.

Division of Endocrinology, Diabetes and Metabolism, Boston Heart Diagnostics, Framingham, MA, USA; Cardiovascular Nutrition Laboratory, USDA Human Nutrition Research Center at Tufts University, Boston, MA.

Background: Changes in body mass index (ΔBMI) have well-established relationships to changes in high-density lipoprotein (ΔHDL)-cholesterol concentrations; however, their relationships to ΔHDL subfractions are less well understood.

Objective: Assess the associations between ΔHDL and ΔBMI in a very large cohort.

Method: Age and sex-adjusted Δapo A1 concentrations were measured within 10 HDL subfractions in 14,121 women and 13,969 men using two-dimensional HDL-mapping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.12.001DOI Listing
December 2018

Higher long-term adherence to statins in rural patients at high atherosclerotic risk.

J Clin Lipidol 2019 Jan - Feb;13(1):163-169. Epub 2018 Nov 15.

Department of Cardiology, St. Vincent's Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Parkville, Melbourne, Australia.

Background: Rural patients with atherosclerotic cardiovascular disease (ASCVD) experience greater cardiovascular morbidity and mortality than their urban counterparts. Statin therapy is a key component of ASCVD treatment. The extent to which there may be regional differences in long-term adherence to statins is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.004DOI Listing
November 2018

Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey.

J Clin Lipidol 2019 Jan - Feb;13(1):100-108. Epub 2018 Dec 1.

Division of Cardiology, Heart Disease Prevention Program, University of California, Irvine, CA, USA. Electronic address:

Background: Statin therapy remains the primary treatment for mixed dyslipidemia, even with moderate triglyceride (TG) elevations.

Objective: We examined the prevalence of elevated TG levels in adults with and without statin use and the associated 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk.

Methods: We studied 9593 US adults aged ≥20 years (219. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.008DOI Listing
December 2018
1 Read

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.

J Clin Lipidol 2019 Jan - Feb;13(1):138-147. Epub 2018 Nov 30.

Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France. Electronic address:

Background: Patients with heterozygous familial hypercholesterolemia (HeFH) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled in the open-label extension (OLE) study, ODYSSEY OLE (NCT01954394), provide a unique opportunity to investigate effects of 2 doses of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, within the same patient cohort.

Objective: The aim of the study was to characterize long-term efficacy and safety of 2 alirocumab dosages and utility of a dose titration strategy in patients with HeFH.

Methods: After an 8-week washout period, patients with HeFH who completed the LONG TERM study (receiving alirocumab 150 mg every 2 weeks [Q2W]) were eligible to enroll in OLE (n = 214) for up to 40 months' treatment duration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.007DOI Listing
November 2018

Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study.

J Clin Lipidol 2019 Jan - Feb;13(1):129-137.e1. Epub 2018 Dec 1.

Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Background: Early assessment of insulin resistance may be a way of identifying patients at risk as well as monitoring treatments that increase insulin sensitivity and reduce the risk of developing type II diabetes mellitus (T2DM).

Objective: The objective of the study was to evaluate the ability of the Lipoprotein Insulin Resistance Index (LP-IR) to predict incident T2DM in a large cohort.

Methods: LP-IR scores were calculated using 6 lipoprotein particle concentrations and sizes measured by nuclear magnetic resonance spectroscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.009DOI Listing
December 2018

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review.

J Clin Lipidol 2019 Jan - Feb;13(1):31-39. Epub 2018 Nov 3.

Department of Paediatric Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands.

Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that may cause life-threatening cardiovascular disease (CVD) at childhood. Marginal effectiveness of statins in reducing low-density lipoprotein cholesterol (LDL-C) is the reason why extracorporeal removal of LDL-C by lipoprotein apheresis (LA) is recommended at the earliest possible age.

Objective: It is, however, unknown to what extent LA effectively reduces the burden of CVD in children with HoFH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.011DOI Listing
November 2018

Increased usual physical activity is associated with a blunting of the triglyceride response to a high-fat meal.

J Clin Lipidol 2019 Jan - Feb;13(1):109-114. Epub 2018 Nov 20.

Program in Personalized and Genomic Medicine, and Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.

Background: Postprandial lipemia (PPL), defined as a prolonged or elevated rise in triglycerides that accompanies fat feeding, is a significant risk factor for coronary heart disease and associated comorbidities. The impact of PPL on coronary heart disease risk is underscored by the preponderance of each day spent in the postprandial state.

Objective: In this study, we evaluated cross-sectionally the association between usual (ie, noninterventional) physical activity and the 6-hour triglyceride response to a standardized high-fat meal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379118PMC
November 2018
1 Read

Comparing patients' prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid.

J Clin Lipidol 2019 Jan - Feb;13(1):170-175. Epub 2018 Nov 15.

Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical Center, Kansas City, KS, USA; Division of Clinical Pharmacology, Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

Background: Dietary fish oil supplements containing the omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are frequently used for cardiovascular benefit. However, several factors may limit the intake of prescribed doses.

Objective: The objective of this study is to compare the prescribed, patient self-reported, and actual intake of supplemental EPA + DHA doses in a lipid-specialty clinic and identify common barriers and influences to therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.005DOI Listing
November 2018
4 Reads

Postprandial lipid absorption in seven heterozygous carriers of deleterious variants of MTTP in two abetalipoproteinemic families.

J Clin Lipidol 2019 Jan - Feb;13(1):201-212. Epub 2018 Oct 24.

Service de Biochimie métabolique, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix (AP-HP), Paris, France; Faculté de Pharmacie de Paris, Université Paris Descartes, Sorbonne Paris Cité, Unité de Technologies Chimiques et Biologiques pour la Santé, U 1022 INSERM, UMR 8258 CNRS, Paris, France.

Background: Abetalipoproteinemia, a recessive disease resulting from deleterious variants in MTTP (microsomal triglyceride transfer protein), is characterized by undetectable concentrations of apolipoprotein B, extremely low levels of low-density lipoprotein cholesterol in the plasma, and a total inability to export apolipoprotein B-containing lipoproteins from both the intestine and the liver.

Objective: To study lipid absorption after a fat load and liver function in 7 heterozygous relatives from 2 abetalipoproteinemic families, 1 previously unreported.

Results: Both patients are compound heterozygotes for p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.003DOI Listing
October 2018

Severe aortic valve stenosis in a 14-year-old boy with sitosterolemia.

J Clin Lipidol 2019 Jan - Feb;13(1):49-53. Epub 2018 Nov 14.

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

We report a 14-year-old boy finally diagnosed with sitosterolemia, presenting with severe aortic valve stenosis. Genetic analysis revealed homozygous null mutation c.1336 C > T (p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.002DOI Listing
November 2018
8 Reads

JCL roundtable-Lipoprotein(a): The emerging risk factor.

J Clin Lipidol 2018 Nov - Dec;12(6):1335-1345

Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

Lipoprotein(a), or Lp(a), is a major risk factor for atherothrombotic events along with low-density lipoprotein cholesterol and, inversely, high-density lipoprotein cholesterol. Lp(a) also contributes to the progression of calcific aortic stenosis and to the rare occurrence of arterial thrombotic strokes without atherosclerosis in children and younger women. Much has been learned about the inheritance of Lp(a) levels and the relationship between apolipoprotein(a) structure and function. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183046
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.11.003DOI Listing
December 2018
4 Reads

From the editor: Lessons from the East.

Authors:
John R Guyton

J Clin Lipidol 2018 Nov - Dec;12(6):1331-1332

Professor of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.11.001DOI Listing
December 2018
1 Read

Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.

J Clin Lipidol 2019 Jan - Feb;13(1):15-30. Epub 2018 Nov 7.

Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Background: Current data from individual studies present conflicting evidence about the relationship between risk factors and cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (FH).

Objectives: We conducted a systematic review and meta-analysis to quantify the association between various CVD risk factors and CVD in FH.

Methods: We searched MEDLINE, EMBASE, Global Health, the Cochrane Library, and PubMed for English-language studies reporting adjusted-associations between cardiovascular, behavioral, or clinical risk factors and CVD with ≥ 100 participants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.012DOI Listing
November 2018
1 Read

Diagnostic accuracy of ultrasound and MRI for Achilles tendon xanthoma in people with familial hypercholesterolemia: A systematic review.

J Clin Lipidol 2019 Jan - Feb;13(1):40-48. Epub 2018 Nov 7.

Department of Medicine, Centre for Heart and Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Background: Achilles tendon xanthoma (ATX) results from tendon thickening and subclinical inflammation triggered by hypercholesterolemia, and is associated with more severe coronary artery disease and a higher risk of cardiovascular events. The ability to detect ATX by clinical examination is limited, and diagnostic imaging, for instance, using ultrasonography or magnetic resonance imagine (MRI), may improve the identification of ATX. However, the accuracy of ultrasound (US) imaging or MRI in identifying ATX in people with familial hypercholesterolemia (FH) has not been systematically reviewed. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183043
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.10.013DOI Listing
November 2018
13 Reads

GPIHBP1 autoantibody syndrome during interferon β1a treatment.

J Clin Lipidol 2019 Jan - Feb;13(1):62-69. Epub 2018 Oct 24.

Departments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address:

Background: Autoantibodies against glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) cause chylomicronemia by blocking the ability of GPIHBP1 to bind lipoprotein lipase (LPL) and transport the enzyme to its site of action in the capillary lumen.

Objective: A patient with multiple sclerosis developed chylomicronemia during interferon (IFN) β1a therapy. The chylomicronemia resolved when the IFN β1a therapy was discontinued. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379125PMC
October 2018
1 Read

Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease.

J Clin Lipidol 2019 Jan - Feb;13(1):194-200. Epub 2018 Oct 29.

Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.

Background: Tendon xanthomas are accumulations of collagen and macrophages, which contain cholesterol esters and a marker of high risk for coronary artery disease (CAD).

Objective: The aim of the article was to clarify whether the presence of Achilles tendon thickening (ATT) was associated with disease severity and plaque vulnerability in patients with CAD.

Methods: A total of 241 consecutive patients who underwent percutaneous coronary intervention and ATT assessment were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.007DOI Listing
October 2018
1 Read

Severe hypertriglyceridemia is primarily polygenic.

J Clin Lipidol 2019 Jan - Feb;13(1):80-88. Epub 2018 Oct 24.

Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Electronic address:

Background: Hypertriglyceridemia (HTG) is a complex trait defined by elevated plasma triglyceride levels. Genetic determinants of HTG have so far been examined in a piecemeal manner; understanding of its molecular basis, both monogenic and polygenic, is thus incomplete.

Objective: The objective of this study was to characterize genetic profiles of patients with severe HTG, and quantify the genetic determinants and molecular contributors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.006DOI Listing
October 2018
24 Reads

Recurrent tendosynovitis as a rare manifestation of a lipid disorder.

J Clin Lipidol 2019 Jan - Feb;13(1):54-61. Epub 2018 Oct 24.

Department of Internal Medicine V (Nephrology, Rheumatology, Hypertensiology, Endocrinolgy, Diabetology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany; Mannheim Institute of Public Health, Social and Preventive Medicine, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany. Electronic address:

A 33-year-old female had suffered from spontaneously recurrent bursitis and tendosynovitis/enthesitis of the patellar and Achilles tendons for about 10 years. The episodes of immobilization increased. Ultrasound imaging of the swollen and painful tendons showed chronic inflammation with neoangiogenesis within the tendons and hypoechoic lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.005DOI Listing
October 2018
2 Reads

Extremely high levels of high-density lipoprotein cholesterol and increased risk of cardiovascular mortality.

Authors:
Tomoyuki Kawada

J Clin Lipidol 2018 Nov - Dec;12(6):1550-1551. Epub 2018 Oct 30.

Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.010DOI Listing
October 2018

Response to the letter entitled "Extremely high levels of high-density lipoprotein cholesterol and increased risk of cardiovascular mortality" by Dr Kawada.

J Clin Lipidol 2018 Nov - Dec;12(6):1551. Epub 2018 Oct 31.

Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.009DOI Listing
October 2018

Predictors of statin use among older adults: A nationwide cross-sectional study.

J Clin Lipidol 2019 Jan - Feb;13(1):156-162.e1. Epub 2018 Oct 16.

Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia. Electronic address:

Background: Statins comprise a key strategy for the prevention and treatment of arteriosclerotic cardiovascular disease, but prescribing remains suboptimal.

Objectives: The objective of this study was to characterize the predictors of statin use among adults aged ≥65 years.

Methods: A cross-sectional study using Pharmaceutical Benefits Scheme (PBS) data on reimbursed prescriptions for a 10% random sample of the Australian population in 2016 was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.10.002DOI Listing
October 2018
6 Reads

Coronary computed tomography angiogram in familial hypercholesterolemia: A double edge sword.

J Clin Lipidol 2018 Nov - Dec;12(6):1549. Epub 2018 Oct 9.

Monash Cardiovascular Research Centre, MonashHEART, Monash Health, Monash University, Melbourne, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183041
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.014DOI Listing
October 2018
2 Reads

Relationship between erythrocyte phospholipid fatty acid composition and obesity in children and adolescents.

J Clin Lipidol 2019 Jan - Feb;13(1):70-79.e1. Epub 2018 Sep 25.

Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China; Institute of Nutrition & Health, Qingdao University, Qingdao, China. Electronic address:

Background: Observational studies have reported inconsistent results on the association between circulating fatty acids and obesity.

Objective: The objective of this study was to investigate the relationship between erythrocyte phospholipid fatty acid composition and obesity in children and adolescents.

Methods: We conducted a case-control study including 1442 obese and 1442 normal-weight children and adolescents. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183041
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.013DOI Listing
September 2018
5 Reads

Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1.

J Clin Lipidol 2018 Nov - Dec;12(6):1374-1382. Epub 2018 Sep 1.

Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie- Santé, Saint Joseph University, Beirut, Lebanon; INSERM LVTS U1148, Hôpital Bichat-Claude Bernard, Paris, France. Electronic address:

Background: The Middle East region is characterized by low levels of high-density lipoprotein cholesterol (HDL-C). To date, no genetic study has investigated the cause of low HDL-C in the Lebanese population.

Objective: Our objective was to study the genetic causes for hypoalphalipoproteinemia in a Lebanese family with extremely low HDL-C levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.08.013DOI Listing
September 2018
8 Reads

Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence.

J Clin Lipidol 2019 Jan - Feb;13(1):89-99. Epub 2018 Sep 18.

Boston Heart Diagnostics, Framingham, MA, USA. Electronic address:

Background: Triglyceride (TG) concentrations >2000 mg/dL are extremely elevated and increase the risk of pancreatitis.

Objectives: We characterized five cases and two kindreds and ascertained prevalence in a reference laboratory population.

Methods: Plasma lipids and DNA sequences of LPL, GPIHBP1, APOA5, APOC2, and LMF1 were determined in cases and two kindreds. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.007DOI Listing
September 2018
5 Reads

Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention.

J Clin Lipidol 2019 Jan - Feb;13(1):115-122. Epub 2018 Sep 22.

3rd Medical Department with Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria; Sigmund Freud University, Medical School, Vienna, Austria.

Background: Patients with familial hypercholesterolemia (FH) are at increased risk for premature and subsequent cardiovascular disease. Data on long-term major adverse cardiovascular events (MACE) in patients with FH after percutaneous coronary intervention (PCI) in the era of high-intensity statins are scarce.

Objective: We assessed the prognostic impact of clinically diagnosed FH on long-term MACE, a composite of all-cause death, myocardial infarction, and ischemic stroke in patients admitted for stable coronary artery disease (SCAD) or acute coronary syndromes (ACSs) undergoing PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.09.012DOI Listing
September 2018
3 Reads

In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction.

J Clin Lipidol 2019 Jan - Feb;13(1):213-217.e1. Epub 2018 Sep 21.

L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France. Electronic address:

Background: Beyond the hepatobiliary pathway, studies have demonstrated that direct transintestinal cholesterol efflux (TICE) of plasma-derived cholesterol may contribute to reverse cholesterol transport. The clinical evidence of TICE in human remains challenged because of the difficulty to discriminate the hepatobiliary and transintestinal routes in vivo.

Objective: To provide the first proof of concept that TICE exists in vivo in humans by demonstrating that plasma labeled cholesterol can be excreted in the feces of patients with complete bile duct obstruction. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.010DOI Listing
September 2018
14 Reads

Decreased GlycA after lifestyle intervention among obese, prediabetic adolescent Latinos.

J Clin Lipidol 2019 Jan - Feb;13(1):186-193. Epub 2018 Sep 22.

Division of Endocrinology and Diabetes, Phoenix Children's Hospital, Phoenix, AZ, USA; Center for Health Promotion and Disease Prevention, College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA; Southwest Interdisciplinary Research Center, Arizona State University, Phoenix, AZ, USA.

Background: Obese youth with prediabetes are at increased risk for premature morbidity and mortality through multiple mechanisms, including increased systemic inflammation. GlycA is a novel measure of systemic inflammation that predicts type II diabetes, cardiovascular events, and all-cause mortality in adults.

Objective: The purpose of the present study was to examine changes in GlycA after lifestyle intervention among obese, prediabetic Latino youth. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379100PMC
September 2018
11 Reads

Biphasic dyslipidemia in a patient with painless thyroiditis.

J Clin Lipidol 2018 Nov - Dec;12(6):1367-1370. Epub 2018 Sep 21.

Toranomon Hospital Saitama Clinic, Saitama, Japan; Center for Health Science, Toranomon Hospital, Tokyo, Japan.

In this case study, we followed the thyroid function and serum lipid levels of a patient with painless thyroiditis. Serum lipid levels were decreased during the hyperthyroid phase and elevated during the hypothyroid phase. Both serum lipid levels and thyroid function returned to normative values following a course of thyroid replacement treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.09.009DOI Listing
September 2018
1 Read

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia.

J Clin Lipidol 2019 Jan - Feb;13(1):123-128. Epub 2018 Sep 17.

Nutrition, Metabolism and Atherosclerosis Clinic, Institut de recherches cliniques de Montréal, Montreal, Québec, Canada; Division of Medical Biochemistry, Department of Medicine, McGill University, Montreal, Québec, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Québec, Canada. Electronic address:

Background: Familial hypercholesterolemia (FH) is the most common genetic disorder of lipoprotein metabolism, affecting 1:250 individuals worldwide. This monogenic disease is associated with lifelong elevation in circulating low-density lipoprotein cholesterol and premature cardiovascular disease (CVD). In 2016, the estimated prevalence of diabetes in Canada was 9%. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.008DOI Listing
September 2018
10 Reads

The spectrum of type III hyperlipoproteinemia.

J Clin Lipidol 2018 Nov - Dec;12(6):1383-1389. Epub 2018 Sep 14.

Centre Hospitalier de l'Universite Laval, Quebec, Quebec, Canada.

Background: Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia characterized by hypercholesterolemia and hypertriglyceridemia due to markedly increased numbers of cholesterol-enriched chylomicron and very-low-density lipoprotein (VLDL) remnant lipoprotein particles. Type III can be distinguished from mixed hyperlipidemia based on a simple diagnostic algorithm, which involves total cholesterol, triglycerides, and apolipoprotein B (apoB). However, apoB is not measured routinely. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183040
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.006DOI Listing
September 2018
15 Reads

A failure of standardization or a failure of the process of standardization.

J Clin Lipidol 2018 Sep - Oct;12(5):1325-1326. Epub 2018 May 18.

Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.009DOI Listing

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

J Clin Lipidol 2018 Sep - Oct;12(5):1234-1243.e5. Epub 2018 May 31.

Department of Medicine, University California San Diego, La Jolla, CA, USA.

Background: Familial chylomicronemia syndrome (FCS) is a rare metabolic disorder caused by mutations in lipoprotein lipase (LPL) or genes required for LPL functionality and is characterized by hyperchylomicronemia that results in recurrent episodes of acute pancreatitis. Owing to the rarity of FCS, there are few case series describing the phenotypic variability in FCS patients in detail.

Objective: To provide baseline characteristics in the largest study population to date of patients with FCS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183024
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.05.013DOI Listing
May 2018
15 Reads

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.

J Clin Lipidol 2018 Sep - Oct;12(5):1199-1207. Epub 2018 May 22.

Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Background: Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is safe and effective in reducing low-density lipoprotein cholesterol in adults with familial hypercholesterolemia. A dedicated study, HAUSER-RCT, is being conducted to examine the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH).

Objective: To present the rationale and design of the HAUSER-RCT study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.007DOI Listing
May 2018
3 Reads

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

J Clin Lipidol 2018 Sep - Oct;12(5):1141-1145. Epub 2018 Jun 1.

Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduces low-density lipoprotein cholesterol levels and improves cardiovascular outcomes. Given the short time frame, these agents have been available for use; reports of nonresponse to the PCSK9 inhibitor therapy are scarce in literature. We describe 2 cases with substantially lesser than expected low-density lipoprotein cholesterol lowering on PCSK9 therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.017DOI Listing
June 2018
1 Read

The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis.

J Clin Lipidol 2018 Sep - Oct;12(5):1133-1140.e15. Epub 2018 Jun 13.

Monash Cardiovascular Research Centre, Monash Heart, Monash Health, Monash University, Melbourne, Australia.

Background: Current guidelines recommend an intensive lipid-lowering therapy to achieve the low-density lipoprotein cholesterol (LDL-C) target in patients with high risk of cardiovascular disease. Former studies suggested adding ezetimibe to statin therapy in the above setting may promote plaque changes; however, this effect has not been consistently reported.

Methods: Electronic searches were performed in MEDLINE, EMBASE, and Cochrane library on November 30, 2017 to identify prospective trials assessing the effects of combined ezetimibe and statin therapy versus statin therapy alone on atheroma volume using intravascular ultrasound. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.06.001DOI Listing
June 2018
1 Read

PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?

J Clin Lipidol 2018 Sep - Oct;12(5):1123-1132. Epub 2018 May 31.

Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Perugia, Italy.

The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183024
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.05.012DOI Listing
May 2018
2 Reads

"Taking a look under the hood"-imaging the phenotypic heterogeneity of familial hypercholesterolemia.

J Clin Lipidol 2018 Sep - Oct;12(5):1095-1098. Epub 2018 Jun 8.

Oregon Health & Science University, Knight Cardiovascular Institute, Center for Preventive Cardiology, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacl.2018.05.020DOI Listing
June 2018
2 Reads

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

J Clin Lipidol 2018 Nov - Dec;12(6):1358-1366. Epub 2018 Sep 11.

Robarts Research Institute, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. Electronic address:

Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease. The principal evidence base for this comes from large population studies focusing on first atherothrombotic events. However, inconsistent findings have been reported from studies investigating the impact of elevated Lp(a) on atherothrombotic events in subjects with preexisting cardiovascular disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183037
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.08.012DOI Listing
September 2018
4 Reads